QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis ...
QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...
HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Qiagen, a global leader in sample to insight solutions, welcomes the publication of a peer-reviewed study, titled “Optimizing tuberculosis infection screening strategies for people living with HIV in ...
Data on performance of QuantiFERON-TB Gold In-Tube test (QFT) and tuberculin skin test (TST) in children with active tuberculosis from high burden countries in the context of micronutrient deficiency ...
AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care QIAGEN and ...
Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk ...